New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2013
UP AFTER EARNINGS: Fusion-IO (FIO), up 18.2%... Akamai (AKAM), up 17.8%... Angie's List (ANGI), up 10.9%... Cliff's (CLF), up 7.6%... Biogen (BIIB), up 3.6%... Dow Chemical (DOW), up 3.3%... Western Digital (WDC), up 3.1%. ALSO HIGHER: Sony (SNE), up 4.3% after raising forecast for FY13 sales and profit... Vodafone (VOD), up 2.6% after Reuters say Verizon (VZ) may bid $100B for full control of Verizon Wireless JV... Cardinal Health (CAH), up 3.6% after signing new supply agreement with CVS Caremark (CVS)... DOWN AFTER EARNINGS: Zynga (ZNGA), down 9.5%... Melanox (MLNX), down 8.6%... Qualcomm (QCOM), down 4.6%... 3M (MMM), down 3.6%... Bristol-Myers (BMY), down 1.6%. ALSO LOWER: Intuit (INTU), down 13.4%, after cutting guidance.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 17, 2015
10:47 EDTSNEPress Conference to unveil new brain injury technology to be held in New York
Subscribe for More Information
10:33 EDTQCOMCiti says Xilinx, not Maxim, likely to be acquired
According to Citi, analog chip maker Maxim Semiconductor (MXIM) probably won't be acquired, despite Bloomberg reports which stated that Texas Instruments (TXN) and Analog Devices (ADI) had held talks about potentially buying the company. The firm sees Xilinx (XLNX) as the only large cap chip maker remaining that has "all of the attributes of a good takeover target." WHAT'S NEW: The only two companies capable of buying Maxim are Texas Instruments and Analog Devices, Citi analyst Christopher Danely wrote in a note to investors today. However, Maxim's valuation is too high for Texas Instruments and the deal would be too big for Analog Devices, the analyst stated. However, Xilinx is a potential takeover target, partly due to its high margins, a size large enough that it could impact an acquirer's profits and its cost cutting opportunities, Danely stated. One potential acquirer of Xilinx is Qualcomm (QCOM), which has suggested that it could be interested in M&A opportunities in the future, the analyst wrote. Despite his belief that Xilinx could be acquired, Danely kept a Neutral rating on the shares. WHAT'S NOTABLE: On October 14, Bloomberg reported that Analog Devices and Maxim were in merger talks. On October 28, the news service reported that Texas Instruments was in talks about buying Maxim. According to Bloomberg, Maxim was working with a bank on a strategic review before it was approached by Analog Devices. Maxim may not want to sell itself unless it receives a large premium, the news service stated. PRICE ACTION: In early trading, Maxim was flat near $38.86 per share, while Xilinx gained 1.5% to $47.83.
10:17 EDTCVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
09:23 EDTANGIAngie's List drops after rejecting IAC offer
Subscribe for More Information
09:15 EDTANGIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.1%... Cheetah Mobile (CMCM), up 7.7%... Eros International (EROS), up 12.8%... Home Depot (HD), up 3.1%...Wal-Mart (WMT), up 2.2%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 14.8% after announcing Phase 1 study results for the company's oral formulation of OCR-002... Fitbit (FIT), up 2.4% after being upgraded to Buy from Neutral at BofA/Merrill. DOWN AFTER EARNINGS: Dicks Sporting Goods (DKS), down 15.4%... Urban Outfitters (URBN), down 12.8%. ALSO LOWER: Osiris Therapeutics (OSIR), up 25.5% after being downgraded to Sell from Hold at Brean Capital... Angie's List (ANGI), down 8.7% after board unanimously determines not to pursue IAC (IACI) proposal... Clovis Oncology (CLVS), down 4.1% after receiving downgrades from Goldman and WallachBeth... Chesapeake Energy (CHK), down 2.5% after being downgraded to Neutral from Buy at Sterne Agee CRT... Cooper Companies (COO), down 2% after being downgraded to Market Perform from Outperform at Wells Fargo.
09:02 EDTSNEAnalyst pans competing products, says buy Fitbit
Shares of previous high-flier Fitbit (FIT) have dropped about 30% in the last two weeks following the company's third quarter earnings report, but an analyst at Bank of America upgraded his view of the fitness tracker maker this morning, saying that now is the time to buy ahead of fourth quarter results that may be boosted by the "underwhelming" new products being launched by its competitors. UNDERWHELMING COMPETITION: Fitbit's sales guidance for this holiday quarter looks conservative, contends Bank of America analyst Nat Schindler, who notes that the company only had the launch of one new product last December but will have the Charge, Charge HR and Surge to drive sales this season. Schindler also notes that the company's international advertising has expanded into more countries ahead of the holidays this year. Key, however, may be the "underwhelming" lineup of new or updated fitness trackers launched by competitors, such as the Microsoft's (MSFT) Band 2, Jawbone's UP4 and Sony's (SNE) Smartband 2, many of which have only minor improvements and no "must have" features to pull consumers away from Fitbit, Schindler told investors in his research note. PLATFORM PICKING UP STEAM: The analyst also pointed out that Fitbit now has more than 20 companies signed onto its health and wellness platform, including big names like Target (TGT) and Barclays (BCS), which he believes should help drive revenue beats in the upcoming fiscal year due to increased device sales. Also, the additional dashboard data should help Fitbit maintain long-term user engagement, said Schindler. APPLE WATCH: Apple's (AAPL) Apple Watch is largely viewed as the biggest potential competitive threat to Fitbit's offerings, but on the fitness tracker maker's last earnings call CEO James Park said Fitbit's products differ from those of its competitors in several key aspects, including pricing, cross-platform compatibility, brand awareness and product line breadth. Other wearables makers include Garmin (GRMN) and Samsung. PRICE ACTION: Since the day after Fitbit's last earnings report after the market close on November 2, its shares have fallen about 29.5% to close yesterday at $28.80. In pre-market trading this morning, Fitbit shares rose 2% to $29.40.
08:54 EDTQCOMMaxim could be bidder for Fairchild, says Citi
Citi analyst Atif Malik views Maxim Integrated (MXIM) as a potential acquirer Fairchild Semiconductor (FCS). Bloomberg on October 13 reported that Fairchild was seeking advice for a potential sale, and listed potential acquirers as STMicroelectronics (STM), Infineon (IFNNY) and ON Semiconductor (ON). Bids from STM and ON seem unlikely, but Infineon and Maxim could be potential acquirers of Fairchild, Malik tells investors in a research note. In a bull case scenario, Fairchild's buyout value could reach $25 per share, the analyst contends. Fairchild closed yesterday at $17.76. Malik's peer at Citi, analyst Christopher Danely, argued today in research note that Maxim Integrated (MXIM) is unlikely to get acquired despite reports of interest from Analog Devices (ADI) and Texas Instruments (TXN). Danely views Xilinx (XLNX) as a potential takeout target, potentially for Qualcomm (QCOM).
08:37 EDTQCOMCiti sees Xilinx, not Maxim, as potential takeout candidate
Citi analyst Christopher Danely says he does not expect Maxim Integrated (MXIM) to get acquired despite reports of interest from Analog Devices (ADI) and Texas Instruments (TXN). Xilinx (XLNX) is the only large-cap semiconductor company left with "all of the attributes of a good takeover target," Danely tells investors in a research note. He believes Xilinx management could be willing sellers at the right price, and points out Qualcomm (QCOM) has a history of doing deals. Xilinx could make a good candidate for Qualcomm, Danely contends.
08:37 EDTCLFCliffs Natural idling iron ore pellet production at Northshore Mining operation
Subscribe for More Information
08:04 EDTMLNXEZchip announces amended merger agreement with Mellanox
Subscribe for More Information
07:31 EDTANGIAngie's List board unanimously determines not to pursue IAC proposal
Subscribe for More Information
07:30 EDTANGIAngie's List board unanimously determines not to pursue IAC proposal
05:33 EDTQCOMStocks with implied volatility below IV index mean; YUM QCOM
Subscribe for More Information
November 16, 2015
17:10 EDTDOWSoros took stake in Paypal, liquidated Herbalife stake
Soros Fund Management gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Paypal (PYPL), CIT Group (CIT), Schlumberger (SLB), Kraft Heinz (KHC), and Amazon (AMZN). INCREASED STAKES: Allergan (AGN), Lions Gate (LGF), Energen (EGN), Southwest Airlines (LUV), and Qunar Cayman Islands (QUNR). DECREASED STAKES: LyondellBasell (LYB), YPF (YPF), Time Warner Cable (TWC), Dow Chemical (DOW), and Monsanto (MON). LIQUIDATED STAKES: Herbalife (HLF), Lennar (LEN), DR Horton (DHI), United Continental (UAL), and Nice Systems (NICE).
15:53 EDTQCOMJANA Partners reduces stakes in Rackspace, Qualcomm
JANA Partners gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Mattel (MAT), Zoetis (ZTS), and Aramark (ARMK). INCREASED STAKES: ConAgra Foods (CAG). DECREASED STAKES: Rackspace (RAX), Qualcomm (QCOM), Time Warner (TWX), Starz (STRZA), and Lions Gate (LGF). LIQUIDATED STAKES: Johnson Controls (JCI), Precision Castparts (PCP), AerCap Holdings (AER), United Rentals (URI), and HD Supply Holdings (HDS).
12:53 EDTAKAMLimelight Networks responds to US Court of Appeals decision
Subscribe for More Information
09:06 EDTCVSDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
08:33 EDTMLNXMellanox's EDR 100Gb/s InfiniBand solution selected by TACC
Mellanox announced that the Texas Advanced Computing Center at The University of Texas in Austin has selected Mellanox's end-to-end 100Gb/s EDR interconnect solutions to develop North America's first end-to-end 100Gb/s EDR high-performance computing cluster.
06:23 EDTMLNXMellanox, EZchip to change pact to include 'go-shop' provision, Reuters says
Subscribe for More Information
06:18 EDTCVSDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use